Tatva Chintan Pharma Chem Limited has delivered exceptional financial performance in Q3 FY26, demonstrating strong operational momentum across its specialty chemicals business. The company's Board of Directors approved the quarterly results on January 21, 2026, following review by the Audit Committee.

Financial Performance Overview

The company's consolidated financial results show substantial growth across key metrics for the quarter ended December 31, 2025:

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Tatva Chintan maintained its strong growth trajectory:

Operational Efficiency Improvements

The company demonstrated improved operational efficiency during Q3 FY26. Total expenses increased to ₹1,154.10 million from ₹861.75 million in Q3 FY25, while revenue growth significantly outpaced expense growth. Cost of materials consumed rose to ₹696.13 million from ₹450.39 million, reflecting higher business volumes. Employee benefits expense increased to ₹168.24 million from ₹132.34 million, indicating continued investment in human resources.

Changes in inventories showed a positive impact of ₹161.92 million in Q3 FY26 compared to ₹46.33 million in the previous year, suggesting improved inventory management and higher production levels.

Standalone vs Consolidated Results

The company's standalone results for Q3 FY26 showed revenue from operations of ₹1,385.88 million compared to ₹839.99 million in Q3 FY25. Standalone net profit reached ₹159.84 million versus a loss of ₹11.65 million in the corresponding quarter last year. The consolidated results include performance from subsidiaries Tatva Chintan USA Inc. and Tatva Chintan Europe B.V.

Regulatory and Compliance Updates

The company implemented changes related to Labour Codes effective November 21, 2025, recognizing an incremental gratuity impact of ₹8.76 million under Employee Benefits Expense. Management assessed this impact as not material to overall financial performance. The financial results were prepared in accordance with Indian Accounting Standards and received an unmodified opinion from statutory auditors NDJ & Co., Chartered Accountants.

Business Segment Focus

Tatva Chintan operates in the specialty chemicals segment as its single reportable business area. The company maintains manufacturing facilities at Ankleswar and Dahej SEZ in Gujarat, with its corporate office and DSIR-approved R&D center located in Vadodara. The strong financial performance reflects the company's continued focus on specialty chemical manufacturing and its ability to capitalize on market opportunities in this sector.

Tatva chintan pharma Chem Limited has scheduled its quarterly earnings call to discuss the financial performance for the third quarter of fiscal year 2026. The company formally notified stock exchanges about this important investor engagement through a regulatory filing dated January 12, 2026.

Earnings Call Schedule Details

The earnings call is scheduled for Wednesday, January 21, 2026, at 5:00 PM Indian Standard Time. This call will focus on discussing the company's financial results for both the quarter and nine months ended December 31, 2025.

Management Participation

The earnings call will be represented by senior management officials who will provide insights into the company's quarterly performance and address investor queries.

Regulatory Compliance

The company has fulfilled its regulatory obligations by informing both major stock exchanges about the earnings call schedule. The notification was sent to BSE Limited and National Stock Exchange of India Limited under Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Coordination and Contact Information

ICICI Securities is coordinating the earnings call, with multiple contact persons available for clarifications and registration assistance. The coordination team includes:

• Mr. Jaideep Goswami, Head of Equities
• Mr. Sanjesh Jain and Mr. Mohit Mishra as primary coordinators
• Mr. Rushad Kapadia, Ms. Seema Sehgal, and Ms. Minali Ginwala for clarifications

The company has also made this information available on its official website at www.tatvachintan.com for broader accessibility to stakeholders and investors interested in the company's quarterly performance discussion.